DELAWARE
|
001-34079
|
11-3516358
|
(State or other jurisdiction of Incorporation)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
15245 Shady Grove Road, Suite 455
Rockville, MD
|
20850
|
|
(Address of principal executive offices)
|
(Zip Code)
|
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 7.01 | Regulation FD Disclosure. |
Item 9.01 | Financial Statements and Exhibits. |
(d) | Exhibits. |
Exhibit No.
|
Description
|
Rexahn Pharmaceuticals, Inc. investor presentation for the Rodman & Renshaw 17th Annual Global Investment Conference, dated September 10, 2015.
|
REXAHN PHARMACEUTICALS, INC.
|
|
Date: September 10, 2015
|
/s/ Tae Heum Jeong
|
Tae Heum Jeong
|
|
Senior Vice President of Finance & Chief Financial Officer
|